Promoting	0	9	O
angiogenesis	10	22	O
via	23	26	O
manipulation	27	39	O
of	40	42	O
VEGF	43	47	B-Gene_or_gene_product
responsiveness	48	62	O
with	63	67	O
notch	68	73	B-Gene_or_gene_product
signaling	74	83	O
.	83	84	O

Promoting	86	95	O
angiogenesis	96	108	O
via	109	112	O
delivery	113	121	O
of	122	124	O
vascular	125	133	B-Gene_or_gene_product
endothelial	134	145	I-Gene_or_gene_product
growth	146	152	I-Gene_or_gene_product
factor	153	159	I-Gene_or_gene_product
(	160	161	O
VEGF	161	165	B-Gene_or_gene_product
)	165	166	O
and	167	170	O
other	171	176	O
angiogenic	177	187	O
factors	188	195	O
is	196	198	O
both	199	203	O
a	204	205	O
potential	206	215	O
therapy	216	223	O
for	224	227	O
cardiovascular	228	242	B-Anatomical_system
diseases	243	251	O
and	252	255	O
a	256	257	O
critical	258	266	O
aspect	267	273	O
for	274	277	O
tissue	278	284	B-Tissue
regeneration	285	297	O
.	297	298	O

The	299	302	O
recent	303	309	O
demonstration	310	323	O
that	324	328	O
VEGF	329	333	B-Gene_or_gene_product
signaling	334	343	O
is	344	346	O
modulated	347	356	O
by	357	359	O
the	360	363	O
Notch	364	369	B-Gene_or_gene_product
signaling	370	379	O
pathway	380	387	O
,	387	388	O
however	389	396	O
,	396	397	O
suggests	398	406	O
that	407	411	O
inhibiting	412	422	O
Notch	423	428	B-Gene_or_gene_product
signaling	429	438	O
may	439	442	O
enhance	443	450	O
regional	451	459	O
neovascularization	460	478	O
,	478	479	O
by	480	482	O
altering	483	491	O
the	492	495	O
responsiveness	496	510	O
of	511	513	O
local	514	519	O
endothelial	520	531	B-Cell
cells	532	537	I-Cell
to	538	540	O
angiogenic	541	551	O
stimuli	552	559	O
.	559	560	O

We	561	563	O
tested	564	570	O
this	571	575	O
possibility	576	587	O
with	588	592	O
in	593	595	O
vitro	596	601	O
assays	602	608	O
using	609	614	O
human	615	620	B-Organism
endothelial	621	632	B-Cell
cells	633	638	I-Cell
,	638	639	O
as	640	642	O
well	643	647	O
as	648	650	O
in	651	653	O
a	654	655	O
rodent	656	662	O
hindlimb	663	671	B-Organism_subdivision
ischemia	672	680	O
model	681	686	O
.	686	687	O

Treatment	688	697	O
of	698	700	O
cultured	701	709	O
human	710	715	B-Organism
endothelial	716	727	B-Cell
cells	728	733	I-Cell
with	734	738	O
DAPT	739	743	B-Drug_or_compound
,	743	744	O
a	745	746	O
gamma	747	752	B-Gene_or_gene_product
secretase	753	762	I-Gene_or_gene_product
inhibitor	763	772	O
,	772	773	O
increased	774	783	O
cell	784	788	B-Cell
migration	789	798	O
and	799	802	O
sprout	803	809	B-Tissue
formation	810	819	O
in	820	822	O
response	823	831	O
to	832	834	O
VEGF	835	839	B-Gene_or_gene_product
stimulation	840	851	O
with	852	856	O
a	857	858	O
biphasic	859	867	O
dependence	868	878	O
on	879	881	O
DAPT	882	886	B-Drug_or_compound
concentration	887	900	O
.	900	901	O

Further	902	909	O
,	909	910	O
delivery	911	919	O
of	920	922	O
an	923	925	O
appropriate	926	937	O
combination	938	949	O
of	950	952	O
DAPT	953	957	B-Drug_or_compound
and	958	961	O
VEGF	962	966	B-Gene_or_gene_product
from	967	971	O
an	972	974	O
injectable	975	985	O
alginate	986	994	O
hydrogel	995	1003	O
system	1004	1010	O
into	1011	1015	O
ischemic	1016	1024	O
hindlimbs	1025	1034	B-Organism_subdivision
led	1035	1038	O
to	1039	1041	O
a	1042	1043	O
faster	1044	1050	O
recovery	1051	1059	O
of	1060	1062	O
blood	1063	1068	B-Organism_substance
flow	1069	1073	O
than	1074	1078	O
VEGF	1079	1083	B-Gene_or_gene_product
or	1084	1086	O
DAPT	1087	1091	B-Drug_or_compound
alone	1092	1097	O
;	1097	1098	O
perfusion	1099	1108	O
levels	1109	1115	O
reached	1116	1123	O
80	1124	1126	O
%	1126	1127	O
of	1128	1130	O
the	1131	1134	O
normal	1135	1141	O
level	1142	1147	O
by	1148	1150	O
week	1151	1155	O
4	1156	1157	O
with	1158	1162	O
combined	1163	1171	O
DAPT	1172	1176	B-Drug_or_compound
and	1177	1180	O
VEGF	1181	1185	B-Gene_or_gene_product
delivery	1186	1194	O
.	1194	1195	O

Direct	1196	1202	O
intramuscular	1203	1216	O
or	1217	1219	O
intraperitoneal	1220	1235	O
injection	1236	1245	O
of	1246	1248	O
DAPT	1249	1253	B-Drug_or_compound
did	1254	1257	O
not	1258	1261	O
result	1262	1268	O
in	1269	1271	O
the	1272	1275	O
same	1276	1280	O
level	1281	1286	O
of	1287	1289	O
improvement	1290	1301	O
,	1301	1302	O
suggesting	1303	1313	O
that	1314	1318	O
appropriate	1319	1330	O
presentation	1331	1343	O
of	1344	1346	O
DAPT	1347	1351	B-Drug_or_compound
(	1352	1353	O
gel	1353	1356	O
delivery	1357	1365	O
)	1365	1366	O
is	1367	1369	O
important	1370	1379	O
for	1380	1383	O
its	1384	1387	O
activity	1388	1396	O
.	1396	1397	O

DAPT	1398	1402	B-Drug_or_compound
delivery	1403	1411	O
from	1412	1416	O
the	1417	1420	O
hydrogels	1421	1430	O
also	1431	1435	O
did	1436	1439	O
not	1440	1443	O
lead	1444	1448	O
to	1449	1451	O
any	1452	1455	O
adverse	1456	1463	O
side	1464	1468	O
effects	1469	1476	O
,	1476	1477	O
in	1478	1480	O
contrast	1481	1489	O
to	1490	1492	O
systemic	1493	1501	O
introduction	1502	1514	O
of	1515	1517	O
DAPT	1518	1522	B-Drug_or_compound
.	1522	1523	O

Altogether	1524	1534	O
,	1534	1535	O
these	1536	1541	O
results	1542	1549	O
suggest	1550	1557	O
a	1558	1559	O
new	1560	1563	O
approach	1564	1572	O
to	1573	1575	O
promote	1576	1583	O
angiogenesis	1584	1596	O
by	1597	1599	O
controlling	1600	1611	O
Notch	1612	1617	B-Gene_or_gene_product
signaling	1618	1627	O
,	1627	1628	O
and	1629	1632	O
may	1633	1636	O
provide	1637	1644	O
new	1645	1648	O
options	1649	1656	O
to	1657	1659	O
treat	1660	1665	O
patients	1666	1674	B-Organism
with	1675	1679	O
diseases	1680	1688	O
that	1689	1693	O
diminish	1694	1702	O
angiogenic	1703	1713	O
responsiveness	1714	1728	O
.	1728	1729	O

